• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Twenty years of biological therapy in an patient with IBD.一位炎症性肠病患者接受生物治疗的二十年历程。
BMJ Case Rep. 2018 Jan 23;2018:bcr-2017-221994. doi: 10.1136/bcr-2017-221994.
2
[Frequency and possible reasons for the loss of response to biological therapy in Crohn's disease after a one-year treatment period].[克罗恩病患者生物治疗一年后失去疗效的频率及可能原因]
Orv Hetil. 2011 Jun 12;152(24):951-7. doi: 10.1556/OH.2011.29128.
3
Outcomes 7 Years After Infliximab Withdrawal for Patients With Crohn's Disease in Sustained Remission.英夫利昔单抗停药后对处于缓解期的克罗恩病患者 7 年的结局。
Clin Gastroenterol Hepatol. 2018 Feb;16(2):234-243.e2. doi: 10.1016/j.cgh.2017.09.061. Epub 2017 Oct 7.
4
Circulating Interleukin 6 and Albumin, and Infliximab Levels Are Good Predictors of Recovering Efficacy After Dose Escalation Infliximab Therapy in Patients with Loss of Response to Treatment for Crohn's Disease: A Prospective Clinical Trial.循环白细胞介素6、白蛋白及英夫利昔单抗水平是克罗恩病治疗反应丧失患者英夫利昔单抗剂量递增治疗后疗效恢复的良好预测指标:一项前瞻性临床试验
Inflamm Bowel Dis. 2015 Sep;21(9):2114-22. doi: 10.1097/MIB.0000000000000475.
5
Risk Factors for Rescue Therapy in Crohn's Patients Maintained on Infliximab After Withdrawal of the Immunomodulator: A Long-Term Follow-Up.英夫利昔单抗维持治疗后停用免疫调节剂的克罗恩病患者挽救治疗的危险因素:一项长期随访研究
Dig Dis Sci. 2017 Nov;62(11):3131-3137. doi: 10.1007/s10620-017-4771-z. Epub 2017 Oct 6.
6
Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease.基于症状、生物标志物和血清药物浓度增加英夫利昔单抗剂量并未增加活动期腔型克罗恩病患者的临床、内镜和无皮质类固醇缓解率。
Gastroenterology. 2018 Apr;154(5):1343-1351.e1. doi: 10.1053/j.gastro.2018.01.004. Epub 2018 Jan 6.
7
[Acute appendicitis in a patient with perianal Crohn's disease receiving infliximab].[一名接受英夫利昔单抗治疗的肛周克罗恩病患者并发急性阑尾炎]
Orv Hetil. 2018 Mar;159(10):405-409. doi: 10.1556/650.2018.30982.
8
Topic infliximab injection for refractory rectal stenosis in Crohn's disease: long-term follow-up in two patients.英夫利昔单抗注射治疗克罗恩病难治性直肠狭窄:2例患者的长期随访
Int J Colorectal Dis. 2017 Sep;32(9):1289-1294. doi: 10.1007/s00384-017-2860-2. Epub 2017 Jul 19.
9
Remission maintained by monotherapy after biological + immunosuppressive combination for Crohn's disease in clinical practice.在临床实践中,克罗恩病经生物制剂与免疫抑制剂联合治疗后采用单一疗法维持缓解。
J Gastroenterol Hepatol. 2016 Jan;31(1):112-8. doi: 10.1111/jgh.13039.
10
Short article: Remicade infusions at home: an alternative setting of infliximab therapy for patients with Crohn's disease.短文:在家进行类克输注:克罗恩病患者英夫利昔单抗治疗的另一种方式
Eur J Gastroenterol Hepatol. 2016 Feb;28(2):222-5. doi: 10.1097/MEG.0000000000000530.

引用本文的文献

1
B-cell Acute Lymphoblastic Leukemia in a Patient With Crohn's Disease After Anti-TNF-Alpha Treatment.一名克罗恩病患者在接受抗TNF-α治疗后发生B细胞急性淋巴细胞白血病。
Cureus. 2025 Jan 13;17(1):e77400. doi: 10.7759/cureus.77400. eCollection 2025 Jan.

本文引用的文献

1
Rheumatological manifestations in inflammatory bowel disease.炎症性肠病的风湿学表现
Ann Gastroenterol. 2011;24(3):173-180.
2
Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy.早期谷浓度和英夫利昔单抗抗体可预测英夫利昔单抗再治疗的安全性和疗效。
Clin Gastroenterol Hepatol. 2014 Sep;12(9):1474-81.e2; quiz e91. doi: 10.1016/j.cgh.2014.01.033. Epub 2014 Jan 29.
3
Safety of infliximab in 10 years of clinical practice.10 年临床实践中 infliximab 的安全性。
Eur J Gastroenterol Hepatol. 2011 Jul;23(7):603-6. doi: 10.1097/MEG.0b013e3283479125.
4
Review article: medical, surgical and radiological management of perianal Crohn's fistulas.综述文章:肛周克罗恩病瘘管的医学、外科和放射学处理。
Aliment Pharmacol Ther. 2011 Jan;33(1):5-22. doi: 10.1111/j.1365-2036.2010.04486.x. Epub 2010 Oct 29.
5
Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study.英夫利昔单抗治疗炎症性肠病的长期安全性:一项单中心队列研究。
Gut. 2009 Apr;58(4):501-8. doi: 10.1136/gut.2008.163642. Epub 2008 Oct 2.
6
Perianal Crohn's disease: overview.肛周克罗恩病:概述
Dig Liver Dis. 2007 Oct;39(10):957-8. doi: 10.1016/j.dld.2007.07.152. Epub 2007 Aug 27.
7
Clinical patterns of Crohn's disease in Greece: a follow-up study of 155 cases.希腊克罗恩病的临床模式:155例病例的随访研究
Digestion. 2000;61(2):121-8. doi: 10.1159/000007744.
8
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.嵌合单克隆抗体cA2治疗克罗恩病的肿瘤坏死因子α短期研究。克罗恩病cA2研究小组。
N Engl J Med. 1997 Oct 9;337(15):1029-35. doi: 10.1056/NEJM199710093371502.

一位炎症性肠病患者接受生物治疗的二十年历程。

Twenty years of biological therapy in an patient with IBD.

作者信息

Mak Wing Yan, Segal Jonathan P, Hart Ailsa

机构信息

IBD Unit, St. Mark's Hospital, Harrow, UK.

出版信息

BMJ Case Rep. 2018 Jan 23;2018:bcr-2017-221994. doi: 10.1136/bcr-2017-221994.

DOI:10.1136/bcr-2017-221994
PMID:29367361
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5786985/
Abstract

This interesting case is the first to our knowledge to report outcomes of a patient with Crohn's disease (CD) treated with the biological drug, infliximab, for around 20 years. The case highlights the positive effect of long-term use of infliximab in achieving and maintaining remission in a patient with CD.In this case, loss of response to infliximab was not dependent on length of exposure to the drug. It also appeared that infliximab was still efficacious after drug holidays, which can be especially important around times of pregnancy. Of interest, 'loss of response' to infliximab occurred at one particular time point. The drug was then reintroduced at a later date, which gave the patient clinical benefit. This case suggests that in some situations infliximab can be reintroduced in patients with previous 'loss of response'.Importantly, in this case, Infliximab had no major adverse effects during the 20 years follow-up.

摘要

据我们所知,这个有趣的病例是首例报告使用生物药物英夫利昔单抗治疗克罗恩病(CD)约20年的患者的治疗结果。该病例突出了长期使用英夫利昔单抗对一名克罗恩病患者实现并维持缓解的积极作用。在这个病例中,对英夫利昔单抗反应丧失并不取决于药物暴露时长。看起来英夫利昔单抗在停药期后仍有效,这在孕期尤其重要。有趣的是,对英夫利昔单抗的“反应丧失”发生在一个特定时间点。之后在晚些时候重新使用该药物,给患者带来了临床益处。这个病例表明,在某些情况下,之前出现过“反应丧失”的患者可以重新使用英夫利昔单抗。重要的是,在这个病例中,英夫利昔单抗在20年的随访期间没有出现重大不良反应。